Essential fatty acids in the treatment of schizophrenia

Drugs of Today

Volumn 33, Issue 1, 1997, Pages 5-17

  Mahadik, Sahebarao P ^a   Evans, Denise R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESSENTIAL FATTY ACID;

DIET; HUMAN; LIPID METABOLISM; REVIEW; SCHIZOPHRENIA;

EID: 0030899514     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Meise, U., Fleischhacker, W. Perceptions on treatment in schizophrenia. Br J Psychiatry 1996, 168: 9-16.
2. Carpenter, W.T. Jr. The treatment of negative symptoms: Pharmacological and methodological issues. Br J Psychiatry 1996, 168 (Suppl. 29): 17-22.
3. Meltzer, H. Pre-clinical pharmacology of atypical antipsychotic drugs: A selective review. Br J Psychiatry 1996, 168: 23-31.
4. Suzuki, K. Chemistry and metabolism of brain lipids. In: Basic Neurochemistry, 3rd Ed. Siegel, G.J., Albers, R.W., Agranoff, B.W., Katzman, R. (Eds.). Little, Brown and Company: Boston 1981, 175-91.
5. Horrocks, L.A, Ansell, G.B., Porcellati, G. (Eds.). Phospholipids in the Nervous System, Vol. 1. Metabolism. Raven Press: New York 1982.
6. Thompson, G.A. Jr. (Ed.). The Regulation of Membrane Lipid Metabolism. 2nd Edition. CRC Press: New York 1992.
7. Stein, Z., Susser, E.S., Saenger, G., Marolla, F. (Eds.). Famine and Human Development: The Dutch Hunger Winter of 1944-45. Oxford University Press: New York 1975.
8. Winick, M. (Ed). Hunger Disease. Plenum Press: New York 1979.
9. Brown, A.S., Sussar, E.S., Lin, S.P., Neugebauer, R., Gorman, J.M. Increased risk of affective disorders in males after second trimester prenatal exposure to the Dutch Hunger Winter of 1944-45. Br J Psychiatry 1995, 166: 601-6.
10. Done, D.J., Johnstone, E.C., Frit, C.D., Golding, J., Shepherd, P.M., Crow, T.J. Complications of pregnancy and delivery in relation to psychosis in adult life: Data from the British perinatal mortality survey sample. Br Med J 1991, 302: 1576-80.
11. Geddes, J.R., Lawrie, S.M. Obstetric complications and schizophrenia: A meta-analysis. Br J Psychiatry 1995, 167: 786-93.
12. Foerster, A., Lewis, S.W., Owens, M.J., Murray, R.M. Low birth weight and family history of schizophrenia predict poor premorbid functioning in psychosis. Schizophr Res 1991, 5: 13-20.
13. Parfitt, D.N. Pellagra in recent psychoses. J Ment Sci 1936, 82: 440-4.
14. Brown, J.S. Jr. Role of selenium and other trace elements in the geography of schizophrenia. Schizophr Bull 1994, 20: 387-98.
15. 3 essential fatty acid deficiency syndrome: Substrate pellagra. Biol Psychiatry 1981, 16: 837-50.
16. Packer, L. (Ed.). Oxygen Radicals in Biological Systems. Methods in Enzymology, Vol. 105. Academic Press: New York 1984.
17. Simopoulos, A.P. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991, 54: 438-63.
18. Torrey F.E. Prevalence studies in schizophrenia. Br J Psychiatry 1987, 150: 598-608.
19. Horrobin, D.F., Glen, A.I.M., Vaddadi, K.S. The membrane hypothesis of schizophrenia. Schizophr Res 1994, 13: 195-208.
20. Mahadik, S.P., Mukherjee, S,. Correnti, E.E., Scheffer, R. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: Comparison with bipolar and normal controls. Psychiatr Res 1996, 63: 133-42.
21. WHO, Geneva. Schizophrenia: An International Follow-up Study. John Wiley and Sons: New York 1980.
22. Sartorious, N., Jablensky A., Korten, A. et al. Early manifestations and first-contact incidence of schizophrenia in different cultures. Psychol Med 1986, 16: 909-28.
23. Jablensky A. Multicultural studies and the nature of schizophrenia: A review. J Royal Soc Med 1987, 80: 162-7.
24. Leff, J., Sartorious, N., Jablensky, A., Korten, A., Ernberg, G. The international pilot study of schizophrenia: Five-year follow-up findings. Psychol Med 1992, 22: 131-45.
25. van der Velde, C.D. Variability in schizophrenia. Arch Gen Psychiatry 1976, 33: 489-96.
26. Jeste, D.V., Kleinman, J.E., Potkin, S.G., Luchins, D.J., Weinberger, D.R. Ex uno multi: Subtyping the schizophrenic syndrome. Biol Psychiatry 1982, 17: 199-222.
27. Bloom, F. Advancing neurodevelopmental origin for schizophrenia. Arch Gen Psychiatry 1993, 50: 224-7.
28. Nasrallah, H.A. Neurodevelopmental pathogenesis of schizophrenia. Psychiatr Clin 1993, 16: 269-80.
29. Fish, B., Marcus, J., Hans, S., Auerbach, J.G. Perdue, S. Infants at risk for schizophrenia: Sequelae of a genetic neurointegrative defect. Arch Gen Psychiatry 1992, 49: 221-35.
30. Gottesman, I. (Ed.). Schizophrenia Genesis: The Origins of Madness. WH Freeman Press: New York 1991.
31. Fuller Torrey, E. Stalking the schizovirus. Schizophr Bull 1988, 14: 223-9.
32. Stein, Z., Susser, E.S., Saenger, G., Marolla, F. Nutrition and mental performance. Science 1973, 178: 708-13.
33. DeLisi, L.E. Neuroimmunology: Clinical studies of schizophrenia and other psychiatric disorders. In: The Neurology of Schizophrenia. Nasrallah, H.A., Weinberger, D.R. (Eds.). Elsevier Science Publishers: Amsterdam 1986, 377-96.
34. Horrobin, D.F. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandin Leukotr Essent Fatty Acids 1996, 55: 3-8.
35. Roberts, G.W., Crow, T.J. The neuropathology of schizophrenia - A progress report. Br Med Bull 1987, 43: 599-615.
36. Hyde, T.M., Casanova, M.F., Kleinman, J.E., Weinberger, D.R. Neuroanatomical and neurochemical pathology in schizophrenia. In: Reviews of Psychiatry, Vol. 10. Tasman, A., Goldfinger, S.M. (Eds.). New York 1991, 7-23.
37. Zipursky, R.B., Lim, K.O., Sullivan, E.V. et al. Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry 1992, 49: 195-205.
38. Selemon, L.D., Rajkowska, G., Goldman-Rakic, P.S. Abnormally high neuronal density in the schizophrenic cortex. Arch Gen Psychiatry 1995, 52: 805-18.
39. Carlsson, A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988, 1: 179-203.
40. Davis, K.L., Kahn, R.S., Ko, G., Davidson, M. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 1991, 148: 1474-86.
41. Reynolds, G.P. Beyond the dopamine hypothesis: The neurochemical pathology of schizophrenia. Br J Psychiatry 1989, 155: 305-16.
42. Carlsson, M., Carlsson, A. Interaction between glutaminergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease. TINS 1990, 13: 272-6.
43. 3H-Spiperone binding sites in post-mortem brains from schizophrenic brains. J Neural Trans 1989, 75: 1-10.
44. Tandon, R., Greden, J.F. Cholinergic hyperactivity and negative schizophrenic symptoms: A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 1989, 46: 745-53.
45. Kahn, R.S., Davidson, M., Knott, P., Stern, R.G., Apter, S., Davis, K.L. Effects of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Arch Gen Psychiatry 1993, 50: 599-605.
46. 46. Krystal, J.H., Seibyl, J.P., Price, L.H. et al. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry 1993, 50: 624-35.
47. Hudson, C.J., Young, L.T., Li, P.P., Warsh, J.J. CNS signal transduction in the pathophysiology and pharmacology of affective disorders and schizophrenia. Synapse 1993, 13: 278-93.
48. Agranoff, B. Lipids. In: Basic Neurochemistry, 4th Ed. Siegel, G.J., Albers, R.W., Agranoff, B.W., Katzman, R. (Eds.). Little, Brown and Company: Boston 1989, 91-107.
49. Rana, R.S., Hokin, L.E. Role of phosphoinositols in transmembrane signaling. Physiol Rev 1990, 70: 115-64.
50. 2 and arachidonic acid release in signal transduction. Biochem Soc Trans 1990, 18: 503-7.
51. Rotrosen, J., Wolkin, A. Phospholipidandprostaglandin hypotheses of schizophrenia. In: Psychopharmacology: The Third Generation of Progress. Meltzer, H.Y. (Ed.). Raven Press: New York 1987, 759-64.
52. Keshavan, M.S., Mallinger, A.G., Pettegrew, J.W., Dippold, C. Erythrocyte membrane phospholipids in psychotic patients. Psychiatr Res 1993, 49: 89-95.
53. Mahadik, S.P., Mukherjee, S., Correnti, E. et al. Distribution of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophr Res 1994, 13: 239-47.
54. 31P-NMR spectroscopy detects altered brain metabolism before onset of schizophrenia. Arch Gen Psychiatry 1991, 48: 1112-3.
55. Pettegrew, J.W., Keshavan, M.S. et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. Arch Gen Psychiatry 1991, 48: 563-8.
56. Glen, A.I.M., Glen, E.M.T., Horrobin, D.F. et al. A red cell membrane abnormality in a sub-group of schizophrenic patients: Evidence for two disease. Schizophr Res 1994, 12: 53-61.
57. Peet, M., Horrobin, D.F., Reynolds, G.P. Arachidonic acid: A common link in the biology of schizophrenia. Arch Gen Psychiatry 1994, 51: 665-6.
58. Yao, J.K., van Kammen, D.P., Welker, J.A., Gurklis, J. Red blood cell membrane dynamics in schizophrenia: Correlation of fatty acid abnormalities with clinical measures. Schizophr Res 1994, 13: 227-32.
59. Horrobin, D.F., Manku, M.S., Hillman, S., Glen, I.A.M. Fatty acid levels in brains of schizophrenics and normal controls. Biol Psychiatry 1991, 30: 795-805.
60. Dennis, E.A., Rhee, S.-G., Billah, M.M., Hannum, Y.A. Role of phospholipase in generating lipid second messenger signal transduction. FASEB J 1991, 5: 2068-77.
61. Farooqui, A.A., Hirashima, Y., Horrocks, L.A. Brain PLAs and their role in signal transduction. In: Neurobiology of Essential Fatty Acids. Bazan, N.G. et al. (Eds.). Plenum Press: New York 1992, 11-25.
62. 2 activity in schizophrenia: A replication study. Biol Psychiatry 1990, 28: 495-501.
63. 2 activity in schizophrenics and other psychiatric patients. Biol Psychiatry 1993, 34: 641-9.
64. Mahadik, S.P., Gowda, S. Antioxidants in the treatment of schizophrenia. Med Actual/Drugs Today 1996, 32: 553-65.
65. Cadet, J.L., Lohr, J.B. Free radicals and the developmental pathophysiology of schizophrenic burnout. Integr Psychiatry 1987, 5: 40-8.
66. Mahadik, S.P., Mukherjee, S. Free radical pathology and antioxidant defense in schizophrenia: A review. Schizophr Res 1996, 19: 1-18.
67. Mahadik, S.P., Shendarkar, N.S., Scheffer, R.E., Mukherjee, S., Correnti, E.E. Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls. Prostaglandin Leukotr Essent Fatty Acids 1996, 55: 65-70.
68. Christinsen, O., Christinsen, E. Fat consumption and schizophrenia. Acta Psychiatr Scand 1988, 78: 587-91.
69. Dougherty, R.M., Galli, C., Ferro-Luzzi, A. Lipid and phospholipid fatty acid composition of plasma, red blood cells, and platelets and how they are affected by dietary lipids: A study of normal subjects from Italy, Finland and the USA. Am J Clin Nutr 1987, 45: 443-55.
70. Mellor, J.E., Laugharne, J., Peet, M. Schizophrenic symptoms and dietary intake of n-3 fatty acids. Schizophr Res, in press.
71. Hudson, C. J., Lin, A., Horrobin, D. F. Phospholipases: In search of a genetic base of schizophrenia. Prostaglandin Leukotr Essent Fatty Acids 1996, 55: 119-22.
72. Vaddadi, K.S., Courtney, P., Gilleard, C.J. et al. A double-blind trial of essential fatty acids supplementation in patients with tardive dyskinesia. Psychiatr Res 1989, 27: 313-23.
73. Vaddadi, K.S. Use of γ-linoleic acid in the treatment of schizophrenia and tardive dyskinesia. Prostaglandin Leukotr Essent Fatty Acids 1992, 46: 67-70.
74. Wolkin, A., Jordan, B., Peselow, E., Rubinstein, , M., Rotrosen, J. Essential fatty acid supplementation in tardive dyskinesia. Am J Psychiatry 1986, 143: 912-4.
75. Mellor, J.E., Laugharne, J., Peet, M. Omega-3 fatty acid supplementation in schizophrenic patients. Hum Psychopharmacol, in press.
76. Peet, M., Laugharne, J., Mellor, J.E., Ramchand, C.N. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandin Leukotr Essent Fatty Acids 1996, 55: 119-22.
77. Vaddadi, K. Dyskinesias and their treatment with essential fatty acids: A review. Prostaglandin Leukotr Essent Fatty Acids 1996, 55: 89-94.
78. Wainwright, P.E. Do essential fatty acids play a role in brain and behavioral development? Neurosci Biobehav Rev 1992, 16: 193-205.
79. Anderson, G.J., Connor, W.E., Corliss, J.D. Docosahexaenoic acid is the preferred dietary fatty acid for the development of the brain. Pediatr Res 1990, 27: 89-97.
80. Nandi, D.N., Banerjee, G., Boral, G.C. et al. Socio-economic status and prevalence of mental disorders in certain rural communities in India. Acta Psychiatr Scand 1979, 59: 276-93.
81. Carlson, S.E., Carver, J.D., House, S.G. High fat diets varying in ratios of polyunsaturated to saturated fatty acid and linoleic to linolenic acid: A comparison of rat neural and red cell membrane phospholipids. J Nutr 1986, 116: 718-25.
82. Connor, W.E., Lin, D.S., Neuringer, M. Is the docosahexaenoic acid (DHA, 22:6n-3) content of erythrocytes a marker for the DHA content of brain phospholipids? FASEB J 1993, 7: A152.
83. 2 dopamine receptors is reduced in schizophrenia and Huntington diseased brains. Proc Natl Acad Sci USA 1989, 86: 10156-60.
84. 2 receptor synergism. Nature 1991, 353: 164-7.
85. Meyers, D.G., Maloley, P.A., Weeks, D. Safety of antioxidant vitamins. Arch Intern Med 1996, 156: 925-35.
86. Mukherjee, S., Reddy, R., Schnur, D.B. Diabetes mellitus and tardive dyskinesia. Biol Psychiatry 1991, 624-7.
87. 3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc Natl Acad Sci USA 1986, 83: 4021-5.
88. Sinclair, H.M. History of essential fatty acids. In: Omega-6 Essential Fatty Acids: Pathophysiological Role in Clinical Medicine. Horrobin, D.F. (Ed.). Alan R. Liss Inc.: New York 1990, 1-19.
89. Crawford, M.A. Essential fatty acids and neurodevelopmental disorder. In: Neurobiology of Essential Fatty Acids. Bazan, N.G. et al. (Eds.). Plenum Press: New York 1992, 307-14.
90. Yamamoto, N., Saitoh, M., Moriuchi, A., Nomura, M., Okuyama, H. Effect of dietary a-linolenate/linoleate balance on brain lipid compositions and learning ability of rats. J Lipid Res 1987, 28: 144-51.
91. Essali, M.A., Das, R., de Belleroche, J., Hirsch, S.R. The platelet polyphosphoinositite system in schizophrenia: The effects of neuroleptic treatment. Biol Psychiatry 1990, 28: 478-87.
92. Kaiya, H., Nishida, A., Imai, A., Nakashima, S., Nozawa, Y. Accumulation of diacylglycerol in platelet phosphoinositides turnover in schizophrenia: A biological marker of good prognosis? Biol Psychiatry 1989, 26: 669-76.
93. Yao, J.K., Yasaei, P., van Kammen, D.P. Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostaglandin Leukotr Essent Fatty Acids 1993, 46: 39-46.
94. Mahadik, S.P., Mukherjee, S., Correnti, E.E., Scheffer, R. Altered signal transduction in fibroblasts from first-episode schizophrenic patients. Biol Psychiatry 1996, 39: 519.
95. Davidson, B., Kurstjens, N.P., Patton, J., Cantrill, R.C. Essential fatty acids modulate apomorphine activity at the dopamine receptors in cat caudate slices. Eur J Pharmacol 1988, 149: 317-22.
96. Virdee, K., Brown, B.L., Dobson, P.R.M. Stimulation of arachidonic acid release from swiss 3T3 cells by recombinant basic fibroblast growth factor: Independence from phosphoinositide turnover. Biochim Biophys Acta 1994, 1220: 171-80.
97. Walicke, P.A. Basic and acidic fibroblast growth factors have trophic effects on neurons from multiple CNS regions. J Neurosci 1988, 8: 2618-27.
98. Allebeck, P. Schizophrenia: A life-threatening disease. Schizophr Bull 1989, 15: 81-9.